Evidence map›Paper›PMID 30680665›Full record

Trial reportInternational journal of hematology2019

Optimal dosage of methotrexate for GVHD prophylaxis in umbilical cord blood transplantation.

Yoshitaka Adachi, Kazutaka Ozeki, Shun Ukai, Ken Sagou, Nobuaki Fukushima, Akio Kohno

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yoshitaka AdachiDepartment of Hematology and Oncology, Konan Kosei Hospital, 137, Omatsubara,Takaya-cho, Konan, 483-8704, Aichi, Japan. adachi_y0216@yahoo.co.jp.ORCID http://orcid.org/0000-0002-9763-5533
Kazutaka OzekiDepartment of Hematology and Oncology, Konan Kosei Hospital, 137, Omatsubara,Takaya-cho, Konan, 483-8704, Aichi, Japan.
Shun UkaiDepartment of Hematology and Oncology, Konan Kosei Hospital, 137, Omatsubara,Takaya-cho, Konan, 483-8704, Aichi, Japan.
Ken SagouDepartment of Hematology and Oncology, Konan Kosei Hospital, 137, Omatsubara,Takaya-cho, Konan, 483-8704, Aichi, Japan.
Nobuaki FukushimaDepartment of Hematology and Oncology, Konan Kosei Hospital, 137, Omatsubara,Takaya-cho, Konan, 483-8704, Aichi, Japan.
Akio KohnoDepartment of Hematology and Oncology, Konan Kosei Hospital, 137, Omatsubara,Takaya-cho, Konan, 483-8704, Aichi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The combination of methotrexate (MTX) and a calcineurin inhibitor is widely used for GVHD prophylaxis in umbilical cord blood transplantation (UCBT). However, the optimal MTX dosage for GVHD prophylaxis in UCBT remains unclear. In the present study, we investigated the impact of MTX dosage on clinical outcomes following UCBT in a single-center retrospective study. Of 70 UCBT recipients included in this study, 37 received MTX at doses of 10 mg/m

Indexed as

Cord Blood Stem Cell TransplantationAdultAgedAllograftsFemaleGraft vs Host DiseaseHumansMaleMethotrexateMiddle AgedRetrospective StudiesTacrolimusMethotrexateTacrolimusEndothelial cell damageGraft-versus-host diseaseMethotrexateUmbilical cord blood transplantation

Identifiers

PMID30680665

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.